Drugs Made In America Acquisition II Corp. updates CFO and CEO compensation, grants equity upon business combination

Drugs Made In America Acquisition II Corp.

CFO Saleem Elmasri's monthly fee remains $3,500; equity grant increases from 100,000 to 175,000 shares earned at execution of definitive agreement.
CEO Roger Bendelac receives $4,500/month ($2,500 current, $2,000 deferred) and 250,000 shares earned upon signing a definitive business combination agreement.
Both equity grants are to be issued at closing of the initial business combination, within ten days thereafter.
Updated Statement of Work with Titan Advisory Services LLC and CEO Compensation Agreement with Aleutian Equity Holdings LLC were entered on April 22, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.